GlassScriptPhysician profile
Muhammad Naqvi
NPI 1316269533
$35,602.79
in general payments reported to CMS, 2019-2025
66 companies · $38.52 in 2025
The $38.52 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $968 · 2020: $3,855 · 2021: $8,663 · 2022: $21K · 2023: $842 · 2024: $131 · 2025: $38.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $579 · Long Term Medical Supply Or Device Loan: $382 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $579.17 |
| Long Term Medical Supply Or Device Loan | $382.43 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $22,396.06 | 2019-2022 | |
| Morphosys, US INC. | $1,535.25 | 2021-2022 | |
| Kite Pharma, INC. | $1,443.96 | 2020-2022 | |
| Aveo Pharmaceuticals, INC. | $1,097.41 | 2022 | |
| Novartis Pharmaceuticals Corporation | $915.81 | 2019-2024 | |
| Janssen Biotech, INC. | $786.28 | 2020-2022 | |
| Amgen INC. | $605.63 | 2019-2023 | Kyprolis |
| Seagen INC. | $563.02 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $538.39 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $533.68 | 2019-2023 | Keytruda |
| Genzyme Corporation | $382.42 | 2019-2023 | |
| Celgene Corporation | $363.82 | 2019-2024 | Reblozyl |
| Eisai INC. | $352.22 | 2019-2022 | |
| Pfizer INC. | $276.03 | 2019-2025 | |
| Daiichi Sankyo INC. | $238.62 | 2019-2022 |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Naqvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.